The stock of Ocera Therapeutics Inc (NASDAQ:OCRX) is a huge mover today! The stock increased 7.56% or $0.15 on November 23, hitting $2.2. About 358,220 shares traded hands or 55.28% up from the average. Ocera Therapeutics Inc (NASDAQ:OCRX) has declined 27.39% since April 22, 2016 and is downtrending. It has underperformed by 32.80% the S&P500.
The move comes after 6 months positive chart setup for the $50.43 million company. It was reported on Nov, 24 by Barchart.com. We have $2.33 PT which if reached, will make NASDAQ:OCRX worth $3.03M more.
Analysts await Ocera Therapeutics Inc (NASDAQ:OCRX) to report earnings on March, 2. They expect $-0.30 EPS, up 11.76% or $0.04 from last year’s $-0.34 per share. After $-0.32 actual EPS reported by Ocera Therapeutics Inc for the previous quarter, Wall Street now forecasts -6.25% EPS growth.
Ocera Therapeutics Inc (NASDAQ:OCRX) Ratings Coverage
Out of 2 analysts covering Ocera Therapeutics (NASDAQ:OCRX), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Ocera Therapeutics has been the topic of 3 analyst reports since November 6, 2015 according to StockzIntelligence Inc. The stock of Ocera Therapeutics Inc (NASDAQ:OCRX) has “Buy” rating given on Friday, November 4 by Aegis Capital. The rating was initiated by Brean Capital with “Buy” on Tuesday, February 23.
According to Zacks Investment Research, “Ocera Therapeutics, Inc. is a biopharmaceutical company. It focused on the development and commercialization of proprietary compounds to treat acute and chronic orphan liver diseases. Ocera Therapeutics, Inc., formerly known as Tranzyme, Inc., is based in San Diego, California.”
Insitutional Activity: The institutional sentiment increased to 1.22 in 2016 Q2. Its up 0.60, from 0.62 in 2016Q1. The ratio is positive, as 3 funds sold all Ocera Therapeutics Inc shares owned while 10 reduced positions. 2 funds bought stakes while 6 increased positions. They now own 6.77 million shares or 0.29% less from 6.79 million shares in 2016Q1.
Vanguard Grp Inc has invested 0% of its portfolio in Ocera Therapeutics Inc (NASDAQ:OCRX). Pura Vida Lc reported 131,000 shares or 0.11% of all its holdings. Great Point Prtnrs Ltd Liability Com last reported 1.07% of its portfolio in the stock. Millennium Ltd owns 516,343 shares or 0% of their US portfolio. Deutsche Financial Bank Ag last reported 82 shares in the company. Northern holds 0% or 12,786 shares in its portfolio. The Texas-based Dimensional Fund L P has invested 0% in Ocera Therapeutics Inc (NASDAQ:OCRX). Tower Research Lc (Trc) accumulated 0% or 343 shares. Endurant Capital Mgmt Lp reported 103,142 shares or 0.07% of all its holdings. State Bank Of New York Mellon Corporation, a New York-based fund reported 34,136 shares. Renaissance Limited Liability Co reported 169,100 shares or 0% of all its holdings. The Massachusetts-based Geode Cap Mgmt Ltd Llc has invested 0% in Ocera Therapeutics Inc (NASDAQ:OCRX). Turner Invests L P holds 0.08% or 139,716 shares in its portfolio. Moreover, Blackrock Fund has 0% invested in Ocera Therapeutics Inc (NASDAQ:OCRX) for 46,236 shares. Royal Bancorp Of Canada reported 3,293 shares or 0% of all its holdings.
Insider Transactions: Since October 13, 2016, the stock had 1 insider purchase, and 0 insider sales for $6,598 net activity. The insider Bukofzer Stan bought $6,598.
Another recent and important Ocera Therapeutics Inc (NASDAQ:OCRX) news was published by Seekingalpha.com which published an article titled: “Ocera Therapeutics: A Speculative Investment” on April 19, 2016.
OCRX Company Profile
Ocera Therapeutics, Inc., incorporated on January 12, 1998, is a clinical-stage biopharmaceutical company. The Firm is focused on acute and chronic orphan liver diseases. The Firm is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger. The Firm relies on third-party manufacturers to produce bulk drug substance and drug products required for commercial use and for its clinical trials.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.